Orally Disintegrating Tablet Technology Trends and Forecast
The future of the global orally disintegrating tablet technology market looks promising with opportunities in the pharmaceutical, nutraceutical, and chewable vitamin markets. The global orally disintegrating tablet technology market is expected to grow with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are increasing demand for patient-friendly dosage forms, growing prevalence of geriatric population globally, and rising convenience and ease of administration for pediatric and elderly patients.
• Lucintel forecasts that lyophilization is expected to witness the highest growth over the forecast period.
• Within this market, pharmaceutical is expected to witness the highest growth.
• North America is expected to witness highest growth over the forecast period.
United States: Recent developments in the US include PfizerÄX%$%Xs announcement of advancements in orally disintegrating tablet (ODT) technology for pediatric patients, aligning with FDAÄX%$%Xs emphasis on pediatric drug development. Government initiatives aim to streamline ODT regulatory pathways, fostering innovation in the pharmaceutical sector.
India: Indian pharmaceutical companies like Sun Pharma are investing in ODT technology to cater to the growing demand for patient-friendly dosage forms. Government initiatives such as the PLI scheme incentivize domestic ODT production, aiming to boost the countryÄX%$%Xs pharmaceutical exports.
China: Chinese companies like Huahai Pharmaceutical are focusing on ODT R&D to meet the rising domestic demand for convenient drug delivery systems. Government targets include fostering indigenous ODT technology and promoting international collaborations to enhance competitiveness in the global ODT market.
Germany: Recent developments in Germany feature BayerÄX%$%Xs initiatives to improve ODT formulations for geriatric patients, aligning with the countryÄX%$%Xs aging population trends. Government support for ODT innovation is evident through funding programs targeting advancements in drug delivery systems, emphasizing patient-centric healthcare solutions.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Orally Disintegrating Tablet Technology by Segment
The study includes a forecast for the global orally disintegrating tablet technology by type, application, and region.
Orally Disintegrating Tablet Technology Market by Type [Shipment Analysis by Value from 2018 to 2030]:
• Lyophilization
• Compressed Tablets
• Cotton Candy Process
Orally Disintegrating Tablet Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Pharmaceutical
• Nutraceuticals
• Chewable Vitamin
Orally Disintegrating Tablet Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Orally Disintegrating Tablet Technology Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies orally disintegrating tablet technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the orally disintegrating tablet technology companies profiled in this report include-
• Catalent
• SPI Pharma
• Takeda Pharmaceutical
• Fuisz Technologies
• Roquette
• JRS Pharma
• Fuji Chemical
• Merck
• Galvita
• DAICEL
Recent Development in the Orally Disintegrating Tablet Technology Market
Pfizer: Pfizer announced the development of a new orally disintegrating tablet formulation for one of its blockbuster drugs, aiming to enhance patient compliance and convenience. The innovative formulation is expected to facilitate easier administration, particularly for pediatric and geriatric populations.
Teva Pharmaceuticals: Teva Pharmaceuticals introduced a novel ODT technology leveraging fast-dissolving excipients, enhancing the bioavailability and efficacy of their existing drug portfolio. This advancement underscores TevaÄX%$%Xs commitment to improving patient adherence and experience through innovative drug delivery solutions.
Novartis: Novartis unveiled a strategic collaboration with a leading biotech firm to co-develop ODT formulations for a range of therapeutic areas. This partnership aims to leverage synergies in drug development expertise and ODT technology to accelerate the delivery of novel treatments to patients worldwide.
AstraZeneca: AstraZeneca announced the successful completion of clinical trials for its ODT formulation of a key cardiovascular medication. The fast-dissolving tablet demonstrated superior efficacy and rapid onset of action compared to conventional oral dosage forms, positioning it as a potential game-changer in the treatment of cardiovascular diseases.
Merck & Co.: Merck & Co. revealed plans to expand its ODT product line with the launch of a new over-the-counter medication for allergy relief. The innovative formulation offers rapid symptom relief without the need for water, catering to consumers seeking convenient and portable allergy management solutions.
Features of the Global Orally Disintegrating Tablet Technology Market
Market Size Estimates: Orally disintegrating tablet technology market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Orally disintegrating tablet technology market size by type, application, and region in terms of value ($B).
Regional Analysis: Orally disintegrating tablet technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the orally disintegrating tablet technology market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the orally disintegrating tablet technology market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for orally disintegrating tablet technology market?
Answer: The global orally disintegrating tablet technology market is expected to grow with a CAGR of 7.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the orally disintegrating tablet technology market?
Answer: The major drivers for this market are increasing demand for patient-friendly dosage forms, growing prevalence of geriatric population globally, and rising convenience and ease of administration for pediatric and elderly patients.
Q3. What are the major segments for orally disintegrating tablet technology market?
Answer: The future of the global orally disintegrating tablet technology market looks promising with opportunities in the pharmaceutical, nutraceutical, and chewable vitamin markets.
Q4. Who are the key orally disintegrating tablet technology market companies?
Answer: Some of the key orally disintegrating tablet technology companies are as follows:
• Catalent
• SPI Pharma
• Takeda Pharmaceutical
• Fuisz Technologies
• Roquette
• JRS Pharma
• Fuji Chemical
• Merck
• Galvita
• DAICEL
Q5. Which orally disintegrating tablet technology market segment will be the largest in future?
Answer: Lucintel forecasts that lyophilization is expected to witness the highest growth over the forecast period.
Q6. In orally disintegrating tablet technology market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the orally disintegrating tablet technology market by type (lyophilization, compressed tablets, and cotton candy process), application (pharmaceutical, nutraceuticals, and chewable vitamin), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Orally Disintegrating Tablet Technology Market, Orally Disintegrating Tablet Technology Market Size, Orally Disintegrating Tablet Technology Market Growth, Orally Disintegrating Tablet Technology Market Analysis, Orally Disintegrating Tablet Technology Market Report, Orally Disintegrating Tablet Technology Market Share, Orally Disintegrating Tablet Technology Market Trends, Orally Disintegrating Tablet Technology Market Forecast, Orally Disintegrating Tablet Technology Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.